Social media and Essure hysteroscopic sterilization: a perfect storm


Like Comment
Related Content

Volume 111, Issue 6, Pages 1105–1106


Steven R. Lindheim, M.D., M.M.M.a, Jody Lynee Madeira, J.D., Ph.D.b, Bala Bagavath, M.D.c, John C. Petrozza, M.D.d


Over the past several years, the commercial status of the Essure Coil, a permanent hysteroscopic sterilization device, has switched from assured to pressured. In July 2018, the device's manufacturer, Bayer Healthcare, announced that it would halt sales in the United States (the last country in which the device has been offered) by year's end. This decision was prompted by years of declining sales revenue and came after thousands of women filed complaints of adverse events, including device expulsion, uterine and tubal perforation, intractable pelvic pain, and bleeding necessitating hysterectomy, device-related death, unintended pregnancy and miscarriage, and a variety of other chronic symptoms (1).

Read the full text here.

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. 


Go to the profile of Steven R. Lindheim, MD, MMM
over 2 years ago

A perfect storm that will eventually find smooth sailing.